Related Experiment Video
Updated: Nov 20, 2025

Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance
Published on: May 2, 2018
Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants
Zishuo Cheng1, Christopher R Bethel2, Pei W Thomas3
1Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Abstract:
Metallo-β-lactamases (MBLs) are a growing clinical threat because they inactivate nearly all β-lactam-containing antibiotics, and there are no clinically available inhibitors. A significant number of variants have already emerged for each MBL subfamily. To understand the evolution of imipenemase (IMP) genes (blaIMP) and their clinical impact, 20 clinically derived IMP-1 like variants were obtained using site-directed mutagenesis and expressed in a uniform genetic background in Escherichia coli strain DH10B. Strains of IMP-1-like variants harboring S262G or V67F substitutions exhibited increased resistance toward carbapenems and decreased resistance toward ampicillin. Strains expressing IMP-78 (S262G/V67F) exhibited the largest changes in MIC values compared to IMP-1. In order to understand the molecular mechanisms of increased resistance, biochemical, biophysical, and molecular modeling studies were conducted to compare IMP-1, IMP-6 (S262G), IMP-10 (V67F), and IMP-78 (S262G/V67F). Finally, unlike most New Delhi metallo-β-lactamase (NDM) and Verona integron-encoded metallo-β-lactamase (VIM) variants, the IMP-1-like variants do not confer any additional survival advantage if zinc availability is limited. Therefore, the evolution of MBL subfamilies (i.e., IMP-6, -10, and -78) appears to be driven by different selective pressures.
Insights
Metallo-β-lactamases (MBLs) are a growing threat, with IMP variants showing increased carbapenem resistance. Their evolution is driven by distinct selective pressures, unlike other MBLs.
Area of Science:
- Microbiology
- Molecular Biology
- Evolutionary Biology
Background:
- Metallo-β-lactamases (MBLs) pose a significant clinical challenge due to their ability to neutralize β-lactam antibiotics.
- No inhibitors for MBLs are currently available, and numerous variants have emerged within MBL subfamilies.
Purpose of the Study:
- To investigate the evolution of imipenemase (IMP) genes (blaIMP) and their clinical implications.
- To understand the molecular mechanisms behind increased antibiotic resistance in IMP variants.
Main Methods:
- Site-directed mutagenesis was used to generate 20 clinically derived IMP-1 like variants in Escherichia coli DH10B.
- Biochemical, biophysical, and molecular modeling studies were performed to compare key IMP variants (IMP-1, IMP-6, IMP-10, IMP-78).
- Minimum inhibitory concentration (MIC) values were assessed for various IMP variants.
Main Results:
- IMP-1 like variants with S262G or V67F substitutions demonstrated enhanced resistance to carbapenems and reduced resistance to ampicillin.
- The IMP-78 (S262G/V67F) variant exhibited the most substantial changes in MIC values compared to IMP-1.
- Unlike NDM and VIM variants, IMP-1 like variants did not provide a survival advantage under limited zinc conditions.
Conclusions:
- The evolution of IMP-6, IMP-10, and IMP-78 variants is influenced by unique selective pressures.
- Understanding these evolutionary dynamics is crucial for developing strategies against MBL-mediated antibiotic resistance.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Antimicrobial Effectiveness
Mutations in Microorganisms
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...